C. Su

Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration

G. Pond, G. Sonpavde, J. Tward, 2021, BJU international.

Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer

N. Agarwal, O. Smaletz, E. Antonarakis, 2021, JCO precision oncology.

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.

T. Choueiri, N. Agarwal, B. Costello, 2020, JAMA oncology.

Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.

G. Sonpavde, A. Alva, L. Marandino, 2021, Clinical genitourinary cancer.

Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).

O. Smaletz, E. Antonarakis, P. Barata, 2021 .

Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.

G. Sonpavde, M. Milowsky, Yilun Sun, 2021 .

Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis.

N. Johnson, J. Warner, G. Lyman, 2022, Blood Cancer Discovery.